BMS withdraws top drug from PBAC

By Megan Brodie 3 years ago | In Companies, Products, Regulatory
  • 3 years ago
Oesophageal cancer, istock.com/dr_microbe

7 June 2021 BMS has withdrawn its blockbuster checkpoint inhibitor from PBAC consideration in one…

This is subscriber-only content. Please login to continue reading.